Login | Register

Genetic Test To Decide Whether Erbitux Works For Colon Cancer Patients Approved By FDA

Up until now, some colorectal cancer (CRC) patients and their doctors had no way of determining whether the drug Erbitux (cetuximab) would be a helpful treatment based on the absence of a KRAS gene mutation. On July 6, 2012, the United States Food and Drug Administration (FDA) approved the first genetic test to help doctors decide which colon cancer patients might respond well to cetuximab...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *